Ideas

Lifespan extension therapy: 15-deoxy-Delta,12,14-prostaglandin J2 (15d-PGJ2) may increase life span via up-regulation of its target gene BubR1, 16/November/2017, 10.10 am
Lifespan extension therapy: 15-deoxy-Delta,12,14-prostaglandin J2 (15d-PGJ2) may increase life span via up-regulation of its target gene BubR1, 16/November/2017, 10.10 am 960 720 Dr Boomi's Genom-2-Discovery Center

 What they say: Introduction:  A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School…

read more

Molecular therapy for glucose homeostasis and TIIDM: Butylphthalide (3-n-butylphthalide or NBP), found in celery oil,  increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 16/November/2017, 5.59 am
Molecular therapy for glucose homeostasis and TIIDM: Butylphthalide (3-n-butylphthalide or NBP), found in celery oil,  increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 16/November/2017, 5.59 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel shows that…

read more

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Epalrestat, an aldose reductase inhibitor used in the treatment of Diabetic Neuropathy, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 16/November/2017, 5.43 am
Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Epalrestat, an aldose reductase inhibitor used in the treatment of Diabetic Neuropathy, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 16/November/2017, 5.43 am 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more

Molecular therapy for Diabetic nephropathy (DN):  Atorvastatin (trade name: Lipitor), a lipid-lowering medication, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 15/November/2017, 5.38 am
Molecular therapy for Diabetic nephropathy (DN):  Atorvastatin (trade name: Lipitor), a lipid-lowering medication, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 15/November/2017, 5.38 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular…

read more

Molecular therapy for middle aged TIIDM patients: Fidarestat,an alodose reductase inhibitor used to control diabetic complications, decreases DNA-PPK expression, suppresses phosphorylation of HSP90a, increases AMPK activity, augments mitochondrial biogenesis and energy metabolism, promotes weight loss and exercise endurance and alleviates TIIDM via down regulation of its target gene, 15/November/2017, 5.26 am
Molecular therapy for middle aged TIIDM patients: Fidarestat,an alodose reductase inhibitor used to control diabetic complications, decreases DNA-PPK expression, suppresses phosphorylation of HSP90a, increases AMPK activity, augments mitochondrial biogenesis and energy metabolism, promotes weight loss and exercise endurance and alleviates TIIDM via down regulation of its target gene, 15/November/2017, 5.26 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Laboratory of Obesity and Aging Research, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA; and Laboratory…

read more

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Victoza/Saxenda, a drug used in the treatment of TIIDM and Obesity,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 15/September/2017, 5.14 am
Molecular therapy for TIIDM and obesity-associated metabolic deficits: Victoza/Saxenda, a drug used in the treatment of TIIDM and Obesity,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 15/September/2017, 5.14 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite…

read more
Start Typing